Head-to-head evidence
AC-101 vs OD-07656
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: RIPK2 · full Ulcerative Colitis pipeline
AC-101
Developed by Accropeutics (Accro Bioscience)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2027 · NCT07755241 (registry estimate)
OD-07656
Developed by Odyssey Therapeutics
NCT06206811 · Phase 1 · completed
All participants across every part of this study received OD-07656 itself, with no placebo or control group and only single-blinding of the participant, so there is no comparison group to assess safety findings against; results have not yet been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AC-101's landscape · OD-07656's landscape